259 related articles for article (PubMed ID: 24559090)
21. Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
Aigner J; Marmé F; Smetanay K; Schuetz F; Jaeger D; Schneeweiss A
Anticancer Res; 2013 Aug; 33(8):3407-13. PubMed ID: 23898112
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
Stinchcombe TE
Nanomedicine (Lond); 2007 Aug; 2(4):415-23. PubMed ID: 17716129
[TBL] [Abstract][Full Text] [Related]
23. Nab-paclitaxel: a flattering facelift.
Viúdez A; Ramírez N; Hernández-García I; Carvalho FL; Vera R; Hidalgo M
Crit Rev Oncol Hematol; 2014 Dec; 92(3):166-80. PubMed ID: 25048167
[TBL] [Abstract][Full Text] [Related]
24. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
25. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
Chirgwin J; Chua SL
Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
[TBL] [Abstract][Full Text] [Related]
26. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
Guarneri V; Dieci MV; Conte P
Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications.
Kudlowitz D; Muggia F
Expert Opin Drug Saf; 2014 Jun; 13(6):681-5. PubMed ID: 24749649
[No Abstract] [Full Text] [Related]
29. Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer.
Hoy SM
Drugs; 2014 Oct; 74(15):1757-68. PubMed ID: 25260887
[TBL] [Abstract][Full Text] [Related]
30. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.
Wiedenmann N; Valdecanas D; Hunter N; Hyde S; Buchholz TA; Milas L; Mason KA
Clin Cancer Res; 2007 Mar; 13(6):1868-74. PubMed ID: 17363543
[TBL] [Abstract][Full Text] [Related]
31. Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.
Villaruz LC; Socinski MA
Eur J Cancer; 2016 Mar; 56():162-171. PubMed ID: 26875112
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.
Ciruelos E; Jackisch C
Expert Rev Anticancer Ther; 2014 May; 14(5):511-21. PubMed ID: 24575935
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer.
Moreno-Aspitia A; Perez EA
Future Oncol; 2005 Dec; 1(6):755-62. PubMed ID: 16556053
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Blum JL; Savin MA; Edelman G; Pippen JE; Robert NJ; Geister BV; Kirby RL; Clawson A; O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 7(11):850-6. PubMed ID: 18269774
[TBL] [Abstract][Full Text] [Related]
36. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
Aapro M; Tjulandin S; Bhar P; Gradishar W
Breast; 2011 Oct; 20(5):468-74. PubMed ID: 21843943
[TBL] [Abstract][Full Text] [Related]
37. Albumin-bound paclitaxel in solid tumors: clinical development and future directions.
Kundranda MN; Niu J
Drug Des Devel Ther; 2015; 9():3767-77. PubMed ID: 26244011
[TBL] [Abstract][Full Text] [Related]
38. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
Lipp HP
Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
Gradishar WJ; Tjulandin S; Davidson N; Shaw H; Desai N; Bhar P; Hawkins M; O'Shaughnessy J
J Clin Oncol; 2005 Nov; 23(31):7794-803. PubMed ID: 16172456
[TBL] [Abstract][Full Text] [Related]
40. Albumin-bound paclitaxel: a next-generation taxane.
Gradishar WJ
Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
